Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year end

Published 04/05/2020, 13:23
Updated 04/05/2020, 13:25
GILD
-
GSK
-
ALNY
-
VIR
-

(Reuters) - Vir Biotechnology Inc (O:VIR) and Alnylam Pharmaceuticals Inc (O:ALNY) have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday.

The companies plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss accelerating their filing for starting the trials of the inhaled therapy.

Shares of Vir Biotech climbed 4% to $29, while Alnylam's stock rose 1.6% to $131 in premarket trading.

Gilead Sciences Inc 's (O:GILD) antiviral drug remdesivir on Friday won the FDA's emergency use authorization for treating COVID-19 patients.

Vir and Alnylam's therapy candidate, VIR-2703, uses gene-silencing RNA interference (RNAi) technology that targets and silences specific genetic material, blocking the production of deadly proteins that cause diseases.

The companies also plan to identify up to three additional drug candidates to treat COVID-19, and potentially other coronavirus diseases.

Vir received a $250 million (201.29 million pounds)investment from British drugmaker GlaxoSmithKline Plc (L:GSK) last month as part of a collaboration to develop antibody treatments for COVID-19.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.